Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$4.09 +3.3%	$2.87	$1.17 ▼ $13.36	$65.48M	0.05	5.30 million shs	5.31 million shs
ETON Eton Pharmaceuticals	$17.53 +1.4%	$15.20	$4.47 ▼ $21.48	$470.16M	1.13	362,680 shs	124,738 shs
IOBT IO Biotech	$1.63 -3.0%	$1.73	$0.66 ▼ $2.79	$113.32M	0.44	1.24 million shs	307,698 shs
NGM NGM Biopharmaceuticals	$1.54	$1.55	$0.60 ▼ $4.69	$128.53M	1.27	1.47 million shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	-24.43%	-21.43%	+132.94%	+221.95%	-62.44%
ETON Eton Pharmaceuticals	-1.03%	+4.41%	+14.97%	-8.67%	+282.30%
IOBT IO Biotech	-2.33%	-10.64%	-30.00%	+38.84%	+5.66%
NGM NGM Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTAI BioXcel Therapeutics	4.5405 of 5 stars	3.3	5.0	0.0	4.5	3.1	1.7	0.6
ETON Eton Pharmaceuticals	2.1769 of 5 stars	3.5	1.0	0.0	0.0	2.6	1.7	0.6
IOBT IO Biotech	3.1179 of 5 stars	3.7	3.0	0.0	0.0	2.6	2.5	0.6
NGM NGM Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTAI BioXcel Therapeutics	2.67	Moderate Buy	$39.75	871.88% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	69.23% Upside
IOBT IO Biotech	3.33	Buy	$8.67	431.70% Upside
NGM NGM Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IOBT, NGM, BTAI, and ETON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/26/2025	BTAI BioXcel Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00
8/12/2025	IOBT IO Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $4.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTAI BioXcel Therapeutics	$2.27M	28.85	N/A	N/A	($6.73) per share	-0.61
ETON Eton Pharmaceuticals	$39.01M	12.05	N/A	N/A	$0.89 per share	19.70
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A
NGM NGM Biopharmaceuticals	$4.42M	29.10	N/A	N/A	$1.80 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTAI BioXcel Therapeutics	-$59.60M	-$12.64	N/A	N/A	N/A	-5,869.82%	N/A	-134.45%	11/13/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	35.06	N/A	-7.10%	-0.73%	-0.22%	11/11/2025 (Estimated)
IOBT IO Biotech	-$95.49M	-$1.58	N/A	N/A	N/A	N/A	-281.82%	-169.29%	11/11/2025 (Estimated)
NGM NGM Biopharmaceuticals	-$142.38M	-$1.72	N/A	N/A	N/A	-3,223.34%	-77.85%	-67.76%	N/A

Latest IOBT, NGM, BTAI, and ETON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IOBT IO Biotech	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A
8/12/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	-$2.45	-$0.15	-$2.45	$0.21 million	$0.12 million
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
NGM NGM Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTAI BioXcel Therapeutics	N/A	0.76	0.74
ETON Eton Pharmaceuticals	1.14	1.77	1.16
IOBT IO Biotech	4.22	1.96	1.96
NGM NGM Biopharmaceuticals	N/A	7.79	7.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTAI BioXcel Therapeutics	30.68%
ETON Eton Pharmaceuticals	27.86%
IOBT IO Biotech	54.76%
NGM NGM Biopharmaceuticals	75.74%

Insider Ownership

Company	Insider Ownership
BTAI BioXcel Therapeutics	21.20%
ETON Eton Pharmaceuticals	16.03%
IOBT IO Biotech	4.80%
NGM NGM Biopharmaceuticals	35.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTAI BioXcel Therapeutics	90	16.01 million	12.62 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
IOBT IO Biotech	30	N/A	N/A	Not Optionable
NGM NGM Biopharmaceuticals	138	83.46 million	53.50 million	Optionable

IOBT, NGM, BTAI, and ETON Headlines

Recent News About These Companies

A TCG offshoot pulls in $400M for biotech startup creation

July 25, 2025 | biopharmadive.comB

Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer

July 10, 2025 | finance.yahoo.com

NGM Biopharmaceuticals Advances in Cancer Cachexia Treatment with NGM120 Study

June 27, 2025 | tipranks.com

Hundreds of tech, biotech, oil, school workers lose Bay Area jobs

May 17, 2025 | eastbaytimes.comE

NGM Bio slims down in strategic pivot, cutting 75% of staff and halting a midstage liver disease program

May 13, 2025 | fiercebiotech.comF

NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the...

February 24, 2025 | macaubusiness.comM

Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US

February 19, 2025 | finance.yahoo.com

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer

February 4, 2025 | finance.yahoo.com

Merck takes stake in NGM amid flurry of pharma deals

December 29, 2024 | pharmaphorum.comP

cricket win win casino

December 29, 2024 | bwsmartcities.businessworld.inB

A venture firm breathes new life into an old NGM drug

December 20, 2024 | biopharmadive.comB

NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/ß-Klotho Agonist Drug Candidate

December 19, 2024 | tmcnet.com

VC firm pens $608M biobucks deal to redirect NGM's MASH drug to rare disease

December 19, 2024 | fiercebiotech.comF

NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate

December 19, 2024 | finance.yahoo.com

Countywide layoffs cool

November 4, 2024 | smdailyjournal.comS

Global Pancreatic Cancer Market Ready to Hit USD 7,541.09 Million by 2033 with a Noteworthy CAGR of 13.5%

October 21, 2024 | fmiblog.comF

NGM steps up in Greater Newcastle

October 16, 2024 | bankingday.comB

VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight

October 8, 2024 | finance.yahoo.com

NGM Energy fits Starlink, virtual machines and cybersecurity with Navarino

September 26, 2024 | thedigitalship.comT

Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

September 24, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOBT, NGM, BTAI, and ETON Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

$4.09 +0.13 (+3.28%)

As of 02:19 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Eton Pharmaceuticals NASDAQ:ETON

$17.53 +0.25 (+1.45%)

As of 02:19 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

IO Biotech NASDAQ:IOBT

$1.63 -0.05 (-2.98%)

As of 02:19 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

NGM Biopharmaceuticals NASDAQ:NGM

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time